Biophytis Targets Mobility Restoration in Patients with Obesity
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
Biophytis Announces New Non-Clinical Data Further Supporting Its Mission to Pioneer the Restoration of Mobility in Patients with Obesity
Biophytis Revolutionizes Sarcopenia
Biophytis Announces its Participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR)
Biophytis Unveils Its Outlook Strategies for 2025
Biophytis Announces Its Participation to the BIOMED FORUM Investor Conference
Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China
Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities
Biophytis Deploys its Partnership Strategy and Signs Two Contracts with Local Agents in Asia
Biophytis Obtains IND Approval from the FDA to Start its Phase 2 OBA Study in Obesity
Biophytis Presented its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in Paris
Delisting of Securities of PHP Ventures Acquisition Corp.; Green Giant Inc.; RMG Acquisition Corp. III; Biophytis SA; OMNIQ Corp.; AIB Acquisition Corporation; Goal Acquisitions Corp.; Applied UV, Inc.; Cue Health Inc.; Twelve Seas Investment Company II; CalAmp Corp.; and ThermoGenesis Holdings, Inc.; from The Nasdaq Stock Market
Biophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million
Biophytis Extends Its Contract With Atlas to Secure Financing for Its Business Activities
Biophytis Announces the Successful Industrial Transfer of BIO101 (20-hydroxyecdysone) Production by its Service Provider Seqens
Biophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity
Biophytis Announces the Design of its Phase 2 OBA Clinical Study in Obesity
Biophytis is Deploying its Partnership Strategy in Obesity
Biophytis Announces Transfer of ADSs to OTC Market
Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program
Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity
Biophytis (BPTS) to Begin Phase II Obesity Study, Stock Up
Why Is Biophytis (BPTS) Stock Up 43% Today?
Biophytis Announces Its 2023 Financial Results and Provides an Update on Its Business Activities
Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Results of the Combined General Meeting on April 2, 2024
Biophytis Presented its Phase 3 Protocol in the Treatment of Sarcopenia
Biophytis Announces Receipt of Nasdaq Notice
Biophytis and Innovation Solutions Pharma Sign a Partnership Agreement to Accelerate Market Access for Sarconeos (BIO101) in Brazil
Biophytis Receives Notice of Delisting From NASDAQ and Announces It Will Request a Hearing Before the NASDAQ Hearings Panel
Biophytis Releases Its Half-Yearly Accounts as of 30 June 2023 and Provides an Update on Its Operations
Biophytis (BPTS) Soars 73% on Partnership With Skyepharma
Biophytis shares surge 41% following Covid partnership with France's Skyepharma
Why Is Biophytis (BPTS) Stock Up 49% Today?
Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)
Biophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19
Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer
Biophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in Sarcopenia
Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York
Biophytis Announces Next Regulatory Steps in Europe and the United States for its COVA Project
Why Is Biophytis (BPTS) Stock Up 18% Today?
Biophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe
Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19
Biophytis Announces $3.8 Million Registered Direct Offering
Russell 2000 ETF Momentum Sparks Volatility In Small Caps
Why Is Biophytis (BPTS) Stock Up 66% Today?
Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound
Biophytis Has Filed with The FDA For Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia
Why Is Biophytis (BPTS) Stock On The Move Today?